Evidence map›Paper›PMID 39494025›Full record

ArticleACS omega2024

A PD-L1-Targeted Probe Cy5.5-A11 for

Xiao-Cheng Cao, Xue-Li Mao, Shan-Shan Lu, Wei Zhu, Wei Huang, Hong Yi, Li Yuan, Jian-Hua Zhou, Zhi-Qiang Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiao-Cheng CaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Xue-Li MaoResearch Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha 410008, China.
Shan-Shan LuResearch Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha 410008, China.
Wei ZhuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Wei HuangResearch Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha 410008, China.
Hong YiResearch Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha 410008, China.
Li YuanDepartment of Nuclear Medicine, The Third Xiangya Hospital, Central South University, Changsha 410013, China.
Jian-Hua ZhouDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhi-Qiang XiaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.ORCID https://orcid.org/0000-0002-5127-586X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PD-L1 is an immune checkpoint molecule mediating cancer immune escape, and its expression level in the tumor has been used as a biomarker to predict response to immune checkpoint inhibitor (ICI) therapy. Our previous study reveals that an 11 amino acid-long ANXA1-derived peptide (named A11) binds and degrades the PD-L1 protein in multiple cancers and is a potential peptide for cancer diagnosis and treatment. Near-infrared fluorescence (NIF) optical imaging of tumors offers a noninvasive method for detecting cancer and monitoring therapeutic responses. In this study, an NIF dye Cy5.5 was conjugated with A11 peptide to develop a novel PD-L1-targeted probe for molecular imaging of tumors and monitor the dynamic changes in PD-L1 expression in tumors.

Identifiers

PMID39494025
PMCPMC11525735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.